Solesence Inc

SLSN remains in a Stage 4 decline with the medium-term bearish bias intact. Price is below the downward-sloping 9/21 EMAs and major moving averages, and a recent oversold bounce was rejected at the EMA resistance, highlighting a favorable sell entry on failed recovery.

• ↑New Chromalume and Whisper technologies expand to adjacent skincare categories.
• ↑Shift in open orders of $47M indicates strong demand.
• ↓Q1 revenue declined to $13M vs. $14.6M YoY due to shipment delays.